Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Applied Biosystems™ SteriSEQ™ Rapid Sterility Testing Kit
GREENER_CHOICE

Catalog No. p-200022110
Change view
Click to view available options
No. of Reactions:
100 Reactions
50 Reactions
2 product options available for selection
Product selection table with 2 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. No. of Reactions
A57186 50 Reactions
A57185 100 Reactions
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 2 options available.
2 options
Catalog No. A57186 Supplier Applied Biosystems™ Supplier No. A57186
Only null left
Add to Cart
Add to Cart

The SteriSEQ Rapid Sterility Testing Kit is a TaqMan-based quantitative PCR (qPCR) kit for the detection of bacteria and fungi in complex bioproduction samples.

The SteriSEQ Rapid Sterility Testing Kit is a TaqMan-based quantitative PCR (qPCR) kit for the detection of bacteria and fungi in complex bioproduction samples. Designed and tested using criteria for rapid bacteria and fungi detection in biotherapeutic manufacturing cell culture lots, the kit meets or exceeds sensitivity and specificity guidance provided in European Pharmacopoeia (E.P 2.6.27) and U.S. Pharmacopoeia (USP1071). The kit can detect 5–25 genome copies per reaction or the equivalent of 5–25 CFU per reaction.

Features of the SteriSEQ Rapid Sterility Testing Kit include:

  • Fast—sample-to-answer turnaround time of less than a day; delivers results in <5 hours
  • Specific—primers/probes designed specifically for bacteria (16S rRNA) and fungi (18S rRNA)
  • Sensitive—detects bacterial and fungal species at 5–25 genome copies per reaction
  • Efficient—minimizes use of sample material by simultaneously testing for bacteria and fungi, preserving precious cells for final product
  • Accurate—discriminatory positive control helps eliminate false positives and an internal positive control helps ensure PCR reaction consistency in the samples

The SteriSEQ Rapid Sterility Testing Kit uses predefined experiment templates that are included with the following versions of AccuSEQ Real‐Time PCR Software for PCR set up, operation, and post-run analysis:

  • AccuSEQ Real‐Time PCR Software 3.2.1 or later (used with the QuantStudio 5 Real‐Time PCR System)
  • AccuSEQ Real‐Time PCR Software 2.2.1 or later (used with the 7500 Fast Real‐Time PCR Instrument)

Specifications

Content And Storage • SteriSEQ™ Assay Mix, 2 x 110 μL; Store at -25°C to -15°C and protect from light
• qPCR Master Mix Plus, 2 x 750 μL; Store at -25°C to -15°C until first thawed, then store at 2°C to 8°C and protect from light
• SteriSEQ™ Discriminatory Positive Control, 2 x 30 μL; Store at -25°C to -15°C
• SteriSEQ™ DNA Dilution Buffer, 1 x 7 mL; Store at -25°C to -15°C until first thawed, then store at room temperature
Detection Method qPCR
Form Liquid
PCR Method qPCR
Reaction Speed Standard
Label or Dye FAM + VIC, ABY, Alexa Fluor 647
Product Line SteriSEQ
Quantity 50 reactions
For Use With (Application) Real Time PCR (qPCR)
No. of Reactions 50 Reactions
Why does the SteriSEQ assay use ABY and Alexa Fluor dyes?

The SteriSEQ Rapid Sterility Testing System was built as a four-plex assay. We also needed a passive reference dye for the 7500 Fast Real-Time PCR System to display the amplification plots. Mastermix option was limited to bactopure (ROX passive reference dye) due to the sensitive nature of the product. FAM and VIC dyes were for fungi and bacteria targets, which were both MGB probes. For multiplex assays, the recommendation is not to use more than 2 MGB probes, so we were limited to QSY dyes for IPC and DPC. It is known that ABY channel tends to cross to ROX and having DPC in ABY channel caused ROX signal to be pulled up for high copy DPC. Therefore, IPC was placed in ABY channel since IPC levels are consistent across wells. This leaves DPC in Alexa/Cy5 channel. Alexa gave a stronger signal and therefore was chosen for DPC.

What are some in-process testing points that the SteriSEQ assay excels in?

The SteriSEQ Rapid Sterility test excels in several in-process testing points, for example:

Cell isolation and initial culture setup:
Sterility of source materials: At the beginning of the process, cell sources are collected. These source materials may be a potential point of contamination and regulatory bodies recommend that they are tested for microbial contaminants before being processed. Contaminants could be introduced from leukapheresis starting material or during handling.

Cell expansion and culture:
Since cells are cultured and expanded over time, in-process sterility testing for microbial contamination (e.g., bacteria, yeast, mold) should be conducted at multiple stages.

Why is in-process sterility testing encouraged?

In-process sterility testing enables the production process remains under control and microbial contamination risks are minimized before final product release. Testing helps ensure the overall safety and quality of the cell therapy product. Detecting contamination early in the manufacturing process (e.g., during cell expansion) can help prevent the continuation of a compromised batch, saving time and resources. This reduces the risk of wasting materials, labor, and other costs associated with manufacturing and testing.

How do the regulatory agencies view qPCR and nucleic acid-based testing (NAT) for sterility testing?

Regulatory agencies, including the FDA, accept qPCR and nucleic acid-based testing (NAT) for sterility as long as they are appropriately validated and produce comparable results to the compendial method within allowable limits established on a case-by-case basis . The FDA's 2024 guideline on ''Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products'' specifies that sterility testing should comply with USP Chapter <71> or use an alternative test method validated according to USP <1223>. USP <1223> provides further guidance on validating alternative methods, such as nucleic acid-based tests for sterility testing. Additionally, USP <1071> and Ph. Eur. 2.6.27 outline a risk-based approach for selecting rapid microbial testing methods, including NAT, for products with short shelf lives.

What is unique about cell-based therapies in regard to sterility?

Cell-based and other living therapies are unique as they cannot be terminally sterilized using heat, filtration, or other methods. Many of these therapies have short shelf lives and often the patient requires infusion as soon as possible following final formulation due to their disease state. Because of this, the FDA and other regulatory agencies can make exceptions to typical sterility requirements. For example, the FDA allows infusion of patients prior to the completion of rapid or traditional growth-based sterility tests provided the test is negative at the time of infusion.

Regarding growth-based sterility testing, the reason growth-based tests take 7 to 14 days or longer is because it takes that long to detect the slowest growing organisms. Fast growers such as E. coli can be detected sooner. A negative result is based on how long it takes to detect the most challenging species.

Why is sterility testing of biological drug products important?

Sterility testing of biological drug products is a regulatory requirement. It helps to ensure patient safety by testing for any harmful microorganisms that may contaminate a drug product. Early detection of contamination allows for timely intervention, such as discarding contaminated batches or implementing corrective actions.

The U.S. Food and Drug Administration (FDA) defines ''sterile'' as the absence of all viable microorganisms in the sample tested. This typically means that a product or substance has undergone a sterilization process to ensure it is free from any living bacteria, viruses, fungi, or other microorganisms. And that the product has been tested with an accepted sterility test method and passed that test. This definition is critical for products such as pharmaceuticals where sterility is essential to ensure safety and efficacy. The FDA provides guidelines and regulations on methods and validation processes both to achieve and maintain sterility in such products and also on tests for sterility.

Does the SteriSEQ assay enable identification of the species detected?

The SteriSEQ assay is not an identification test. The assay uses 2 primer probe sets, one for bacteria and one for fungi, so the assay discriminates at that level. There can be scenarios where extracted DNA that tests positive by the SteriSEQ assay can be further analyzed with MicroSEQ ID workflow to provide an identification to the species level. An example would be a sample that tests positive with the SteriSEQ assay, the contamination is only from one species (or only one bacterial and one fungal species) and contains a level of DNA (as assessed by Ct value) that enables amplification and sequencing in the MicroSEQ ID workflow.

How many fungal and bacterial strains can the SteriSEQ assay identify?

The SteriSEQ Rapid Sterility assay inclusion panel includes over 16,000 bacterial species and 2,600 fungal species. For bacteria, the panel includes gram-positive and gram-negative species, anaerobic and aerobic species. A full list of the inclusion panel is available.

What is the SteriSEQ assay?

The SteriSEQ assay is a real-time, quantitative PCR (qPCR)-based assay for sensitive and specific detection of bacterial and/or fungal DNA in test samples. The assay utilizes TaqMan qPCR assays that target conserved regions in a broad panel of either bacterial or fungal genomes. Although the SteriSEQ assay is intended for use as a presence/absence test, because it utilizes qPCR, changes in target DNA levels in test samples can be monitored over time. This feature enables assessment of viability of organisms in positive test samples, where increasing levels of target DNA, as measured by drop in Ct, indicate replication of the detected microorganisms.

What are the components of the SteriSEQ Rapid Sterility Testing Kit?

The SteriSEQ Rapid Sterility Testing Kit includes the following components:

- SteriSEQ Assay Mix, 2 x 110 µL: Store at -25 degrees C to -15 degrees C and protect from light
- qPCR Master Mix Plus, 2 x 750 µL: Store at -25 degrees C to -15 degrees C until first thawed, then store at 2 degrees C to 8 degrees C and protect from light
- SteriSEQ Discriminatory Positive Control, 2 x 30 µL: Store at -25 degrees C to -15 degrees C
- SteriSEQ DNA Dilution Buffer, 1 x 7 mL: Store at -25 degrees C to -15 degrees C until first thawed, then store at room temperature


For Research Use Only. Not for use in diagnostic procedures.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.